Jacobs Levy Equity Management
NEOS

Jacobs Levy Equity Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Jacobs Levy Equity Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-391,162
Closed -$268K – 1138
2020
Q2 		$268K Buy
391,162
+248,272
+174% +$197K ﹤0.01% 903
2020
Q1 		$107K Buy
142,890
+21,138
+17% +$29.1K ﹤0.01% 957
2019
Q4 		$184K Buy
+121,752
New +$183K ﹤0.01% 946

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management's NEOS Position: Q3 2020 in Review

Jacobs Levy Equity Management sold out of Neos Therapeutics, Inc (NEOS) in Q3 2020, closing a stake of 391,162 shares — an estimated $268K sold.

Jacobs Levy Equity Management first reported a position in NEOS in Q4 2019 and held it in 3 quarters. The position peaked at $268K in Q2 2020. 41 funds tracked by Wall St. Rank hold NEOS as of Q3 2020.

  • Jacobs Levy Equity Management reported no remaining Neos Therapeutics, Inc position as of Q3 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 391,162 Neos Therapeutics, Inc shares in Q3 2020, an estimated $268K.
  • Jacobs Levy Equity Management first reported a position in Neos Therapeutics, Inc in Q4 2019 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Neos Therapeutics, Inc position peaked at $268K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.